Anavex Life Sciences Advances Alzheimer’s Phase 3 Planning as Cash Runway Extends Into Fiscal 2028

Aevex's stock fell 5% after the U.S. Navy halted a $130M drone boat program due to performance issues. The Navy cited hardware limitations and cost-effective alternatives. Aevex acquired the manufacturer, BlackSea Technologies, in September for up to $650M.

Anavex completed ADME and DDI studies for blarcamesine, with 65 and 8 healthy volunteers respectively, and no serious adverse events reported. The FDA cleared the IND for Fragile X syndrome, and a meeting is scheduled to discuss adding pediatric participants to the Phase 3 Rett syndrome trial.

ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology character

Anavex Life Sciences (AVXL) reported FDA clearance for its drug blarcamesine (ANAVEX 2-73) to advance to human trials for Fragile X syndrome. The company completed clinical pharmacology studies for blarcamesine, with no serious adverse events reported. Anavex also plans to meet with the FDA to discuss adding pediatric participants to its Phase 3 Rett syndrome study.

Anavex Life Sciences (AVXL) received FDA clearance to start a Phase 2a trial for blarcamesine in Fragile X syndrome, expanding its clinical development. The trial will involve 60 adult males and assess safety, tolerability, and pharmacokinetics. Blarcamesine has Orphan Drug Designation but is not yet proven effective.

Anavex Life Sciences (AVXL) received FDA clearance for its Investigational New Drug Application to study blarcamesine in Fragile X syndrome. The Phase 2a trial will assess safety, tolerability, and pharmacokinetics in adult males. Blarcamesine previously received FDA Orphan Drug Designation. AVXL shares closed at $1.48, down 0.67%.